Idiopathic Pulmonary Fibrosis clinical trials at UCSD
2 in progress, 1 open to eligible people
Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
open to eligible people ages 40 years and up
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com
San Diego, California and other locations
Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Sorry, accepting new patients by invitation only
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
La Jolla, California and other locations
Last updated: